Beauty industry warns fillers should be classed as high‑risk

The beauty industry is urging the government to classify Botox and dermal fillers as high‑risk medical procedures, warning that a surge in complications, counterfeit products and unqualified practitioners has created a “dangerous vacuum” in public protection. The call follows a wave of recent reports highlighting the normalisation of injectables among young adults and the growing availability of black‑market toxins.

Concerns have intensified after a series of botulism cases linked to illegal, unregulated Botox circulated in the UK last year, prompting hospitals in the North East to temporarily run out of anti‑toxin treatments. Industry leaders say the outbreak exposed the scale of unsafe practice, with rogue injectors offering cut‑price procedures using substances shipped from overseas and administered in homes, hotel rooms and pop‑up clinics.

Professionals working in regulated medical aesthetics warn that injectables are being widely misrepresented as routine beauty treatments, despite carrying risks that include infection, vascular occlusion, nerve damage and, in rare cases, life‑threatening complications. “Cosmetic injectable treatments aren’t off‑the‑cuff beauty appointments; they’re medical procedures,” the British College of Aesthetic Medicine has repeatedly stressed in recent commentary.

The rise of “baby Botox” and preventative injectables among people in their early twenties has further fuelled concern. According to The Independent, demand among 25‑ to 34‑year‑olds now far outstrips the national average, with many young clients seeking increasingly aggressive treatments despite having no clinical need. Practitioners report turning away patients daily, citing unrealistic expectations shaped by social media and a lack of understanding about the risks involved.

The government has proposed a new licensing scheme for non‑surgical cosmetic procedures, including a traffic‑light system that would restrict the highest‑risk treatments to regulated healthcare professionals working in CQC‑registered premises. However, the beauty industry argues that Botox and fillers must be formally placed in the “red” category to prevent further harm.

Campaigners warn that without clear definitions, robust enforcement and tighter product controls, the UK will continue to face a “race to the bottom” in safety standards. They say the combination of soaring demand, cheap black‑market injectables and unqualified practitioners has created a perfect storm — one that will not be resolved until injectables are recognised as high‑risk and regulated accordingly.